インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - hydroquinone,octinoxate,oxybenzone, - crm - 4,5,3;%;w/w - 15g

インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - hydroquinone - lot - 2% - 60ml

インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - soap - 75g

インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - 100ml

インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - coaltar,salicylic acid - lot - 4.25,2;%w/w - 100ml

インド - 英語 - Central Drugs Standard Control Organization

oreva darmo. - risperidone - tab - 1/4;mg - 10/10

インド - 英語 - Central Drugs Standard Control Organization

sundyota - caps - caps

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd -

シンガポール - 英語 - HSA (Health Sciences Authority)

medtronic international, ltd. - cardiovascular - indicated for patients with severe symptomatic native aortic valve stenosis who are judged by a heart team,including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy. indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., society of thoracic surgeons predicted risk of operative mortality score ≥8% or at a ≥15% risk of mortality at 30 days).for patients presenting with severe native bicuspid aortic valve stenosis, the evolut pro+ system is indicated for patients who are at intermediate or greater risk for surgical aortic valve replacement (avr) where intermediate risk is defined as society of thoracic surgeons operative risk score of ≥4% or documented heart team agreement of risk for avr due to frailty or comorbidities.

インド - 英語 - Central Drugs Standard Control Organization

neu-foreva - zolpidem - tab - 10mg - 10